Modality
ASO
MOA
JAK1/2i
Target
AHR
Pathway
Proteasome
ALS
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
Dec 2021
→ Jul 2030
Phase 2Current
NCT05305396
1,602 pts·ALS
2021-12→2030-07·Not yet recruiting
1,602 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-114.3y awayPh2 Data· ALS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2030-07-11 · 4.3y away
ALS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05305396 | Phase 2 | ALS | Not yet recr... | 1602 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |